Avacta Therapeutics (LSE:AVCT) announced two important clinical updates for its lead pre|CISION®-enabled oncology asset, faridoxorubicin (AVA6000), marking further progress toward later-stage development. The company confirmed that a historic maximum dosing restriction linked to free doxorubicin exposure has now been lifted, following Phase 1 data demonstrating a highly favourable cardiac safety profile. According to the update, patients were dosed at close to four times the conventional doxorubicin level, with higher cumulative exposure, without observing severe cardiac toxicity.
In parallel, the company has set out a clearer route to dose selection for upcoming efficacy trials. Final Phase 1b cohorts are being enrolled to compare two dose levels, with the aim of identifying the optimal biologic dose to take forward. Management said these steps strengthen regulatory confidence in the safety profile of the pre|CISION® platform and should help streamline progression into later-stage studies, supporting the wider strategy to advance its tumour-activated oncology pipeline.
From an investment perspective, progress at the clinical level is overshadowed by ongoing financial and market challenges. Weak financial performance and bearish technical indicators continue to weigh on sentiment, while the absence of major partnerships adds to execution risk. Valuation remains unattractive given ongoing losses and the lack of dividend support, despite the scientific advances being reported.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biopharmaceutical and life sciences group focused on oncology through its subsidiary Avacta Therapeutics. The company is developing its proprietary pre|CISION® tumour-activated drug delivery platform, which uses a fibroblast activation protein (FAP)-targeted peptide system to concentrate potent cancer therapies within the tumour microenvironment while reducing exposure to healthy tissue. Its pipeline includes pre|CISION® peptide drug conjugates and Affimer®-based therapies designed to improve tolerability and enable higher, more effective dosing of anticancer treatments.
Leave a Reply